Biotech: I sold all GALT and purchased CNAT. Conatus' drug seems to be very potent - but their clinical path has taken forever hence why the stock is so low. They need to get into a registration trial after all of this time.
GALT will likely get extremely low by the time results are released for CX so I'll probably buy back before then. If the stock doesn't hold a dollar then it will be OTC.
News 
Market Data 
Discover 
